<DOC>
	<DOCNO>NCT02429882</DOCNO>
	<brief_summary>The purpose study assess safety efficacy brodalumab compare placebo participant axial spondyloarthritis . Subjects randomize 1:1 ratio brodalumab placebo first part study . Subjects receive open label brodalumab remainder study . The entire study 312 week duration subject .</brief_summary>
	<brief_title>Study Efficacy Safety Brodalumab Compared With Placebo Subjects With Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Subject fulfills ASAS classification criterion axial spondyloarthritis ( except Crohn 's disease criterion ) &gt; 3 month age onset &lt; 45 year age Subject Bath Ankylosing Spondylitis DIsease Activity Index ( BASDAI ) score great equal 4 screen baseline Subject spinal pain score ( BASDAI question # 2 ) great equal 4 screen baseline Subject adequate therapeutic trial ( least 4 week ) great equal 2 nonsteroidal antiinflammatory drgs ( NSAIDs ) maximum recommend dose unless contraindicate subject intolerant For subject receive nonbiologic DMARDS subject receive treatment great equal 3 month stable doe great equal 4 week prior initiation IM For subject receive oral corticosteroid : subject must stable dose ( exceed equivalent 10 mg prednisone per day ) equal great 4 week prior initiation IMP Complete ankylosis ( fusion ) spine ; Subject positive test tuberculosis Subject plan surgical intervention baeline week 16 Subject active infection history infection follow ( active infection systemic antiinfectives use within 28 day prior first MP dose A serious infection , define require hospitalization intravenous antiinfectives within 8 week prior first IMP dose Recurrent chronic infection active infection , opinion ofthe investigator might cause study detrimental subject ) Subject active Crohn 's disease history Crohn 's disease Subject active ulcerative colitis require daily use immunosuppressive therapy Subject active fibromyalgia within past 12 month Subject prior history great 1 antiTNF therapy ankylose spondylitis Subject use commercially available investigational biologic therapy ankylose spondylitis follow Antitumor necrosis factor ( TNF ) therapy follow : within 1 month prior IMP initiation etanercept within 2 month prior IMP initiation antiTNF agent . Other experimental commercially available biologic therapy ankylose spondylitis within 3 month prior IMP initiation AntiIL17 biologics ( eg , brodalumab , secukinumab , ixekizumab ) antiIL12/IL23 biologic therapy ( eg , ustekinumab , briakinumab ) time Rituximab time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ankylosing Spondyloarthritis ; non-radiographic axial spondyloarthritis</keyword>
</DOC>